MX356640B - Enfermedad cardiovascular. - Google Patents

Enfermedad cardiovascular.

Info

Publication number
MX356640B
MX356640B MX2014001463A MX2014001463A MX356640B MX 356640 B MX356640 B MX 356640B MX 2014001463 A MX2014001463 A MX 2014001463A MX 2014001463 A MX2014001463 A MX 2014001463A MX 356640 B MX356640 B MX 356640B
Authority
MX
Mexico
Prior art keywords
risk
cardiovascular disease
subject
relates
procamor
Prior art date
Application number
MX2014001463A
Other languages
English (en)
Other versions
MX2014001463A (es
Inventor
De La Iglesia Jaume Marrugat
Llanos Roberto Elosua
Fernández Sergio Castillo
Gómez Joan Salgado
Muñoz José María Ordovás
Pérez-Rasilla Eduardo Salas
Original Assignee
Gendiag Exe Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gendiag Exe Sl filed Critical Gendiag Exe Sl
Publication of MX2014001463A publication Critical patent/MX2014001463A/es
Publication of MX356640B publication Critical patent/MX356640B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a un procedimiento para la evaluación del riesgo cardiovascular en un sujeto, caracterizado porque comprende las etapas de determinar en una muestra aislada de dicho sujeto la presencia de polimorfismos en las posiciones 27 dentro de cada una de las secuencias de ácido nucleico de las SEQ ID NO: 1 a 8, en el que la presencia en la posición 27 de C en la SEQ ID NO: 1; C en la SEQ ID NO; 2; T en la SEQ ID NO: 3; C en la SEQ ID NO: 4, C en la SEQ ID NO: 5; C en la SEQ ID NO: 6; T en la SEQ ID NO: 7 y G en la SEQ ID NO:8; es indicativa de riesgo de padecer un episodio cardiovascular, en el que el episodio cardiovascular se selecciona entre el grupo de infarto de miocardio fatal o no fatal, accidente cerebrovascular, angina de pecho, ataques isquémicos transitorios, enfermedad arterial periférica o una combinación de los mismos.
MX2014001463A 2011-08-05 2012-08-01 Enfermedad cardiovascular. MX356640B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11176695.2A EP2554679B1 (en) 2011-08-05 2011-08-05 Genetic markers for cardiovascular disease risk assessment
PCT/EP2012/065020 WO2013020870A1 (en) 2011-08-05 2012-08-01 Cardiovascular disease

Publications (2)

Publication Number Publication Date
MX2014001463A MX2014001463A (es) 2014-05-14
MX356640B true MX356640B (es) 2018-06-07

Family

ID=46604315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001463A MX356640B (es) 2011-08-05 2012-08-01 Enfermedad cardiovascular.

Country Status (14)

Country Link
US (1) US11814673B2 (es)
EP (2) EP2554679B1 (es)
AR (1) AR087445A1 (es)
BR (1) BR112014002856A2 (es)
CA (1) CA2844103C (es)
DK (1) DK2554679T3 (es)
ES (2) ES2573648T3 (es)
HU (1) HUE029534T2 (es)
MX (1) MX356640B (es)
PL (1) PL2554679T3 (es)
PT (1) PT2739750T (es)
SA (1) SA112330754B1 (es)
UY (1) UY34243A (es)
WO (1) WO2013020870A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12077823B2 (en) 2011-08-05 2024-09-03 Genincode Plc Risk assessment for cardiovascular disease
EP2843056B8 (en) * 2013-08-30 2019-06-26 GENINCODE UK, Ltd. Risk markers for cardiovascular disease in patients with chronic kidney disease
US10704097B2 (en) 2014-02-27 2020-07-07 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
WO2015127517A1 (en) * 2014-02-27 2015-09-03 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
US20190295727A1 (en) * 2018-03-23 2019-09-26 American Heart Association, Inc. System and Method for Assessing Heart Health and Communicating the Assessment to a Patient
CN110840891A (zh) * 2018-08-20 2020-02-28 山西医科大学 降压药潘必定（Pempidine）可作为新型抗心律失常药物
CN111354464B (zh) * 2018-12-24 2024-05-17 深圳先进技术研究院 Cad预测模型建立方法、装置以及电子设备
CN109859847A (zh) * 2019-02-15 2019-06-07 京东方科技集团股份有限公司 电子设备、体重管理收益预测装置及存储介质
WO2021185936A1 (en) 2020-03-17 2021-09-23 Chen Zhao System and method for generating personalized treatments
CA3192122A1 (en) * 2020-10-20 2022-04-28 Kevin Wong Methods of assessing risk of developing a disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6159693A (en) 1998-03-13 2000-12-12 Promega Corporation Nucleic acid detection
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20060228715A1 (en) * 2004-03-05 2006-10-12 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
BRPI0807927A2 (pt) 2007-02-21 2014-06-24 Decode Genetics Ehf Métodos para determinar uma susceptibilidade a doença cardiovascular em um indivíduo humano, de identificação de um marcador para uso para avaliar susceptibilidade a doença cardiovascular, para genotipar uma amostra de ácido nucleico, para avaliar um indivíduo para probabilidade de resposta a um agente terapêutico, para predizer prognóstico de um indivíduo diagnosticado com doença cardiovascular, e para monitorar progresso de tratamento de um indivíduo passando por tratamento para doença cardiovascular, kit para avaliar susceptibilidade a doença cardiovascular em um indivíduo humano, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para doença cardiovascular em um indivíduo humano
WO2010113034A2 (en) * 2009-04-01 2010-10-07 Elisabeth Pfuetzner Genotyping for risk of atherosclerosis
PT2264183T (pt) * 2009-06-09 2017-03-14 Gendiag Exe Sl Marcadores de risco para doença cardiovascular
US20110269735A1 (en) * 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Also Published As

Publication number Publication date
ES2573648T3 (es) 2016-06-09
UY34243A (es) 2013-02-28
ES2657746T3 (es) 2018-03-06
SA112330754B1 (ar) 2015-11-08
EP2554679B1 (en) 2016-03-02
EP2739750A1 (en) 2014-06-11
PT2739750T (pt) 2018-02-13
BR112014002856A2 (pt) 2017-02-21
DK2554679T3 (en) 2016-04-04
AR087445A1 (es) 2014-03-26
US20140342355A1 (en) 2014-11-20
WO2013020870A1 (en) 2013-02-14
CA2844103A1 (en) 2013-02-14
HUE029534T2 (hu) 2017-02-28
CA2844103C (en) 2019-03-12
EP2739750B1 (en) 2017-11-15
EP2554679A1 (en) 2013-02-06
WO2013020870A4 (en) 2013-04-25
MX2014001463A (es) 2014-05-14
PL2554679T3 (pl) 2016-09-30
US11814673B2 (en) 2023-11-14

Similar Documents

Publication Publication Date Title
MX2014001463A (es) Enfermedad cardiovascular.
MX2011013243A (es) Marcadores de riesgo para enfermedad cardiovascular.
MX2013014622A (es) Enfermedad tromboembolica.
MX2019015159A (es) Composiciones, metodos y usos para asistir en el diagnostico, pronostico y tratamiento de la fibrosis pulmonar idiopatica.
MX2013006056A (es) Metodos para diagnosticar y tratar trastornos relacionados con la longitud del ojo.
NZ606725A (en) Methods for predicting anti-cancer response
SG179038A1 (en) Compositions and methods for diagnosing autism spectrum disorders
WO2012106385A3 (en) Methods of identifying multiple epitopes in cells
MX2012010853A (es) Anticuerpos anti-lrp6.
MX337203B (es) Novedosas moleculas inhbidoras de jnk.
RU2011116763A (ru) Способ количественного определения термического стресса, которому подвергался фруктовый сок
MX2016002529A (es) Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica.
WO2012112958A3 (en) High-throughput assays to probe leukemia within the stromal niche
EA201400939A1 (ru) Способ получения медетомидина с использованием хлорацетона
WO2012167163A3 (en) Methods and compositions for detecting endometrial or ovarian cancer
MX2014007284A (es) Metodo para etiquetar objetivos intracelulares y extracelulares de leucocitos.
WO2013082249A3 (en) Compositions and methods for prostate cancer analysis
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
WO2012164525A3 (en) Aging biomarkers
GB201101400D0 (en) Detection method
WO2015035403A3 (en) Methods of assessing tumor growth by determining volumetric tumor growth
MY156871A (en) Detection methods for oil palm shell alleles
WO2013040358A3 (en) Assays and compositions for detection of agr2
WO2011102908A3 (en) Biomarkers of musculoskeletal disease
WO2012135657A3 (en) Compositions and methods for diagnosis, preventing and treating intracranial aneurysms

Legal Events

Date Code Title Description
FG Grant or registration